ArticleTranslational lung cancer research2025

Real-world first-line outcomes of alectinib and brigatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: a nationwide South Korean cohort study using the health insurance review and assessment data.

Hee Jun Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.